BOSTON SCIENTIFIC CORP — Director's Dealing 2025

Jan 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2025-01-01

Reporting Person: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-01	Common Stock	M	13907.0000	$0.0000	Acquired	162025.0000	Direct
2025-01-01	Common Stock	F	6425.0000	$89.3200	Disposed	155600.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-01	Performance Share Units	$	M	13907.0000	Disposed	2024-12-31	Common Stock (13907.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4894.0000	Indirect

Footnotes

F1: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F2: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

F3: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.